Mesenchymal Stem Cell Transplantation for Ischemic Diseases:Mechanisms and Challenges
10.1007/s13770-021-00334-3
- Author:
Thi-Tuong VAN NGUYEN
1
;
Ngoc Bich VU
;
Phuc Van PHAM
Author Information
1. Stem Cell Institute, University of Science, Ho Chi Minh City, Viet Nam
- Publication Type:REVIEW ARTICLE
- From:
Tissue Engineering and Regenerative Medicine
2021;18(4):587-611
- CountryRepublic of Korea
- Language:English
-
Abstract:
Ischemic diseases are conditions associated with the restriction or blockage of blood supply to specific tissues. These conditions can cause moderate to severe complications in patients, and can lead to permanent disabilities. Since they are blood vessel-related diseases, ischemic diseases are usually treated with endothelial cells or endothelial progenitor cells that can regenerate new blood vessels. However, in recent years, mesenchymal stem cells (MSCs) have shown potent bioeffects on angiogenesis, thus playing a role in blood regeneration. Indeed, MSCs can trigger angiogenesis at ischemic sites by several mechanisms related to their trans-differentiation potential. These mechanisms include inhibition of apoptosis, stimulation of angiogenesis via angiogenic growth factors, and regulation of immune responses, as well as regulation of scarring to suppress blood vessel regeneration when needed. However, preclinical and clinical trials of MSC transplantation in ischemic diseases have shown some limitations in terms of treatment efficacy. Such studies have emphasized the current challenges of MSC-based therapies. Treatment efficacy could be enhanced if the limitations were better understood and potentially resolved. This review will summarize some of the strategies by which MSCs have been utilized for ischemic disease treatment, and will highlight some challenges of those applications as well as suggesting some strategies to improve treatment efficacy.
